Common TitleECLAIR
Official Title A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
Phase Phase IIA
ClinicalTrials.gov NCT02076178
Treatments
Cabotegravir
Cabotegravir
Tradename:ApretudeOther Names:Injectable cabotegravir, Long-acting injectable cabotegravirClass:Integrase Inhibitors (INSTI)Categories PREP
Funding
IndustryViiV Healthcare
References
- Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331-e340.